Ireland· IE-PA-EU/1/16/1146/001-009
Glyxambi 10 mg/5 mg film-coated tablets
A linagliptin and empagliflozin product containing empagliflozin + linagliptin, registered in Ireland by Boehringer Ingelheim International GmbH. The same ATC class is registered in 13 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Linagliptin and empagliflozin is registered in 13 of 19 countries.
Countries holding a registration under ATC A10BD19 (linagliptin and empagliflozin), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Linagliptin and empagliflozin · ATC A10BD19
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Empagliflozin + Linagliptin
- Manufacturer
- Boehringer Ingelheim International GmbH
- Country
- Ireland (IE)
- ATC code
- A10BD19
- ATC class
- Linagliptin and empagliflozin
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/16/1146/001-009
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Linagliptin and empagliflozin in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaGLYXAMBIBoehringer Ingelheim International GmbH, Ingelheim am Rhein
- SpainGLYXAMBI 10 MG/5 MG COMPRIMIDOS RECUBIERTOS CON PELICULABoehringer Ingelheim International Gmbh
- FinlandGlyxambiBoehringer Ingelheim International GmbH
- United KingdomGlyxambi 10mg/5mg tabletsBoehringer Ingelheim Ltd
- United StatesGlyxambiBoehringer Ingelheim Pharmaceuticals, Inc.
- SwitzerlandGlyxambi
- IcelandGlyxambiBoehringer Ingelheim International GmbH*
- NetherlandsGlyxambi 10 mg/ 5 mg, filmomhulde tablettenBoehringer Ingelheim International GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Glyxambi
- Liechtenstein · Glyxambi
- Norway · Glyxambi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c11808f8-077c-4f58-8952-398de08afd05 GET /v1/drugs/c11808f8-077c-4f58-8952-398de08afd05?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"A10BD",
"A10BD19"
],
"strength": null,
"pa_number": "EU/1/16/1146/001-009",
"substances": [
"Empagliflozin",
"Linagliptin"
],
"legal_basis": "Well-established use application (Article 10a of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may be renewed (B)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about linagliptin and empagliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.